Safety and Immunogenicity Study of an Intranasal Shigella Flexneri 2a Invaplex 50 Vaccine.

Trial Profile

Safety and Immunogenicity Study of an Intranasal Shigella Flexneri 2a Invaplex 50 Vaccine.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2015

At a glance

  • Drugs Shigella flexneri 2A vaccine (Primary)
  • Indications Shigella infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 12 Jan 2010 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top